Cogent Biosciences Stock Market Value
| COGT Stock | USD 37.34 1.00 2.61% |
| Symbol | Cogent |
Is there potential for Biotechnology market expansion? Will Cogent introduce new products? Factors like these will boost the valuation of Cogent Biosciences. Projected growth potential of Cogent fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Cogent Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Investors evaluate Cogent Biosciences using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Cogent Biosciences' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Cogent Biosciences' market price to deviate significantly from intrinsic value.
It's important to distinguish between Cogent Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cogent Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Cogent Biosciences' market price signifies the transaction level at which participants voluntarily complete trades.
Cogent Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Cogent Biosciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Cogent Biosciences.
| 11/23/2025 |
| 02/21/2026 |
If you would invest 0.00 in Cogent Biosciences on November 23, 2025 and sell it all today you would earn a total of 0.00 from holding Cogent Biosciences or generate 0.0% return on investment in Cogent Biosciences over 90 days. Cogent Biosciences is related to or competes with Arcus Biosciences, Immunitybio, Denali Therapeutics, Galapagos, Liquidia Technologies, Ocular Therapeutix, and Agios Pharm. Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined dis... More
Cogent Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Cogent Biosciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Cogent Biosciences upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.46 | |||
| Information Ratio | 0.0425 | |||
| Maximum Drawdown | 14.32 | |||
| Value At Risk | (4.39) | |||
| Potential Upside | 5.17 |
Cogent Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cogent Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Cogent Biosciences' standard deviation. In reality, there are many statistical measures that can use Cogent Biosciences historical prices to predict the future Cogent Biosciences' volatility.| Risk Adjusted Performance | 0.0608 | |||
| Jensen Alpha | 0.1234 | |||
| Total Risk Alpha | (0.08) | |||
| Sortino Ratio | 0.0504 | |||
| Treynor Ratio | 0.1926 |
Cogent Biosciences February 21, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0608 | |||
| Market Risk Adjusted Performance | 0.2026 | |||
| Mean Deviation | 2.37 | |||
| Semi Deviation | 2.35 | |||
| Downside Deviation | 2.46 | |||
| Coefficient Of Variation | 1428.51 | |||
| Standard Deviation | 2.92 | |||
| Variance | 8.54 | |||
| Information Ratio | 0.0425 | |||
| Jensen Alpha | 0.1234 | |||
| Total Risk Alpha | (0.08) | |||
| Sortino Ratio | 0.0504 | |||
| Treynor Ratio | 0.1926 | |||
| Maximum Drawdown | 14.32 | |||
| Value At Risk | (4.39) | |||
| Potential Upside | 5.17 | |||
| Downside Variance | 6.06 | |||
| Semi Variance | 5.53 | |||
| Expected Short fall | (3.10) | |||
| Skewness | 0.2131 | |||
| Kurtosis | (0.18) |
Cogent Biosciences Backtested Returns
Cogent Biosciences secures Sharpe Ratio (or Efficiency) of close to zero, which signifies that the company had a close to zero % return per unit of risk over the last 3 months. Cogent Biosciences exposes twenty-nine different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Cogent Biosciences' Downside Deviation of 2.46, mean deviation of 2.37, and Risk Adjusted Performance of 0.0608 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.01, which signifies a somewhat significant risk relative to the market. Cogent Biosciences returns are very sensitive to returns on the market. As the market goes up or down, Cogent Biosciences is expected to follow. At this point, Cogent Biosciences has a negative expected return of -0.0131%. Please make sure to confirm Cogent Biosciences' value at risk, and the relationship between the jensen alpha and skewness , to decide if Cogent Biosciences performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.08 |
Very weak reverse predictability
Cogent Biosciences has very weak reverse predictability. Overlapping area represents the amount of predictability between Cogent Biosciences time series from 23rd of November 2025 to 7th of January 2026 and 7th of January 2026 to 21st of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Cogent Biosciences price movement. The serial correlation of -0.08 indicates that barely 8.0% of current Cogent Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.08 | |
| Spearman Rank Test | -0.32 | |
| Residual Average | 0.0 | |
| Price Variance | 1.85 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cogent Stock Analysis
When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.